![](/img/cover-not-exists.png)
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease
Benjamin Pariente, Guillaume Pineton de Chambrun, Roman Krzysiek, Marine Desroches, Gauthier Louis, Chiara De Cassan, Clotilde Baudry, Jean-Marc Gornet, Pierre Desreumaux, Dominique Emilie, Jean-FrédéVolume:
18
Year:
2012
Language:
english
Pages:
1
DOI:
10.1002/ibd.21839
File:
PDF, 320 KB
english, 2012